Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant SOX feasibility after neoadjuvant chemoradiotherapy and esophagectomy for resectable esophageal adenocarcinoma
NL-OMON47475Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tegafur and oxaliplatin in esophageal adenocarcinoma (EAC) and esophageal cancer, sponsored by Amsterdam University Medical Center. Primary endpoint: Completion of planned SOX treatment. Started Feb 2015; status: active, not recruiting.
02
Drugs
tegafuroxaliplatin
03
Conditions
esophageal adenocarcinoma (EAC)esophageal cancer
Beyond the preview
Go deeper on NL-OMON47475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47475.